The Preferred Reporting Items for Systematic Review and Meta-Analysis of Diagnostic Test Accuracy studies (PRISMA-DTA): Explanation, Elaboration and Checklist.

Research output: Contribution to journalArticle

Authors

  • Jean-Paul Salameh
  • Patrick M. Bossuyt
  • Trevor A McGrath
  • Brett D Thombs
  • Christopher J Hyde
  • Petra Macaskill
  • Mariska M G Leeflang
  • Daniël A. Korevaar
  • Penny Whiting
  • Johannes B. Reitsma
  • Jérémie F. Cohen
  • Robert A Frank
  • Harriet A Hunt
  • Lotty Hooft
  • Anne W S Rutjes
  • Constantine A. Gatsonis
  • Brooke Levis
  • David Moher
  • Matthew DF McInnes

Colleges, School and Institutes

External organisations

  • Academic Medical Centre, University of Amsterdam
  • Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. m.m.leeflang@amc.uva.nl.
  • Bristol Medical School, University of Bristol, Bristol, United Kingdom
  • University Medical Center Utrecht
  • Paris Descartes University
  • Brown University
  • University of Ottawa
  • Ottawa Hospital Research Institute
  • Community Information and Epidemiological Technologies, Institute of Population Health; University of Ottawa; Ottawa; Canada

Abstract

Systematic reviews of diagnostic test accuracy (DTA) studies are fundamental to the decision-making process in evidence-based medicine. Although such studies are regarded as high-level evidence, these reviews are not always reported completely and transparently. Suboptimal reporting of DTA systematic reviews compromises their validity and generalizability, and subsequently their value to key stakeholders. PRISMA-DTA, an extension of the PRISMA statement, was recently developed to improve the quality of reporting of DTA systematic
reviews. The PRISMA-DTA statement consists of 27 items, of which 8 are unmodified from the original PRISMA statement. This document provides an explanation for the 19 new and modified items, along with their meaning and rationale. Examples of complete reporting are used for each item to illustrate best practices. The PRISMA-DTA statement, this explanation and elaboration document, and the associated web site (http://www.prismastatement.org/Extensions/DTA) provide resources to support the complete and transparent reporting of DTA systematic reviews.

Details

Original languageEnglish
JournalBMJ
Publication statusAccepted/In press - 20 May 2020